scholarly journals Effectiveness of Repeat Courses of Stereotactic Radiosurgery in Patients with Brain Metastases: A Single Institution Experience

Author(s):  
S. Vanderkelen ◽  
A. Saraf ◽  
C.C. Wu ◽  
M. Hwang ◽  
C.H. Tai ◽  
...  
2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi41-vi41
Author(s):  
Ethan Srinivasan ◽  
Emily Lerner ◽  
Ryan Edwards ◽  
Aden Haskell-Mendoza ◽  
David Huie ◽  
...  

Abstract INTRODUCTION Stereotactic radiosurgery (SRS) is a highly effective therapy for newly diagnosed brain metastases. Risk factors for new-onset seizures after SRS have not been well established. In this study, we aimed to characterize the variables predictive of seizure risk. METHODS Patients treated with SRS for newly diagnosed brain metastases were retrospectively reviewed at a single institution. Data on baseline demographics, radiation parameters, and clinical courses were collected. RESULTS 120 patients without previous seizure history were identified. Median age was 65 years (56-70.8) and baseline KPS 90 (80-90). 16 (13%) patients developed new-onset seizures within 3 months of SRS. In analyses comparing patients with and without new-onset seizures, there was no association between new-onset seizures and baseline KPS(90:80, p=0.48), prior resection (31%:28%, p=0.76), prior WBRT (6%:10%, p=1), immunotherapy or chemotherapy within 1 month (31%:21%, p=0.52 and 56%:57%, p=1), primary tumor site (p=0.07), number of lesions (2.2:3, p=0.21), cerebellar (25%:37%, p=0.41) or brainstem involvement (19%:14%, p=0.71), irradiated maximum target diameter (2.8:2.0cm p=0.191), maximum target volume (7.6:2.9 cm3 p=0.133), total dose of radiation (25:20Gy, p = 0.12), or use of fractionation (56%:35%, p=0.11). However, there was a significant difference in the total irradiated target volume (11.6 vs. 3.8 cm3, p=0.019) and a trend toward increased post-treatment seizures among patients with a total irradiated volume greater than 10cm3 (20%:9%, p=0.11, OR 2.4 [0.85-6.4]). Patients with seizures were also more likely to have received steroids (69%:34%, p=0.012) and AEDs (28%:15%, p=0.021) prior to SRS. CONCLUSIONS Our data suggest that total treatment volume is associated with new-onset seizures within 3 months of SRS. The association between seizures and exposure to steroids or AEDs prior to SRS may be a surrogate for neurologic symptoms at presentation. Patients undergoing SRS to larger volumes and necessitating prophylactic steroids or AEDs may benefit from counseling or intensification of anti-seizure therapy.


2010 ◽  
Vol 78 (4) ◽  
pp. 1142-1146 ◽  
Author(s):  
Paul A. Saconn ◽  
Edward G. Shaw ◽  
Michael D. Chan ◽  
Sarah E. Squire ◽  
Annette J. Johnson ◽  
...  

2013 ◽  
Vol 182 (3) ◽  
pp. 481-485 ◽  
Author(s):  
D. Burke ◽  
C. Mascott ◽  
L. Rock ◽  
S. Callinan ◽  
A. Mihai ◽  
...  

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i25-i26
Author(s):  
Matthew Susko ◽  
Michael Garcia ◽  
Lijun Ma ◽  
Jean Nakamura ◽  
David Raleigh ◽  
...  

Abstract BACKGROUND: Recent evidence supports hippocampal sparing during whole brain radiotherapy (HS-WBRT) to improve neurocognitive outcomes in patients with brain metastases (BM). This study sought to quantify the hippocampal dosimetry and treatment efficacy of stereotactic radiosurgery (SRS) to 10 or greater BM to clarify the roles of SRS and WBRT. METHODS: Patients at a single institution treated with SRS to 10 or more BM without WBRT from 1999 to 2016 were retrospectively reviewed. Treatment-related outcomes including overall survival (OS), freedom from progression (FFP), freedom from new metastases (FFNM), and adverse radiation effect (ARE) were quantified. Hippocampal volumes were retrospectively delineated and dosimetry was evaluated in patients treated with upfront SRS. RESULTS: 143 patients with a total of 2198 lesions met criteria for inclusion with 75 patients treated with upfront SRS and 68 treated as salvage from prior WBRT. Median age was 57 (IQR: 46–65) and median KPS 80 (IQR: 70–90). Histologies included breast (n=52), lung (n=49), melanoma (n=30), and other (n=12). Median number of lesions per patient was 13 (IQR 11–17) with median total volume of treatment of 4.1 cc (IQR 2.0–9.9). 12-month FFP per lesion for upfront and salvage treatment was 96.8% (95% CI: 95.5–98.1) and 83.6% (95% CI: 79.9–87.5) respectively (p < 0.001). 12-month FFNM for upfront and salvage FFSRS was 18.8% (95% CI: 10.9–32.3) versus 19.2% (95% CI: 9.7–37.8) respectively (p = 0.90). Mean hippocampal dose was 150 cGy (IQR 100–202). Symptomatic ARE was observed in 2% of patients or 1% of treated lesions. CONCLUSIONS: High rates of local control can be achieved when treating patients with greater than 10 BM with hippocampal doses that are dramatically lower than for HS-WBRT. Hippocampal sparing is readily achievable with expected rates of new metastatic lesions developing in treated patients with low rates of symptomatic ARE.


2018 ◽  
Vol 101 (4) ◽  
pp. 820-829 ◽  
Author(s):  
Katelyn M. Atkins ◽  
Itai M. Pashtan ◽  
Marc R. Bussière ◽  
Kylie H. Kang ◽  
Andrzej Niemierko ◽  
...  

2015 ◽  
Vol 51 ◽  
pp. S670
Author(s):  
J. Ward ◽  
J. Armstrong ◽  
K. Armstrong ◽  
C. Mascott ◽  
P. Thirion ◽  
...  

2017 ◽  
Vol 7 ◽  
Author(s):  
Kevin B. Harris ◽  
Melanie R. Corbett ◽  
Henry Mascarenhas ◽  
Kenneth Stuart Lee ◽  
Hyder Arastu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document